PubRank

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START) (START)

Clinical Trial ID NCT00409188

PubWeight™ 28.77‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00409188

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2013 2.64
2 Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2013 2.59
3 Immunotherapy as a strategy for the treatment of non-small-cell lung cancer. Therapy 2011 1.74
4 Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2012 1.17
5 Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol 2011 1.15
6 Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin Oncol 2013 1.12
7 Emerging developments of chemoradiotherapy in stage III NSCLC. Nat Rev Clin Oncol 2012 1.04
8 Active-specific immunotherapy for non-small cell lung cancer. J Thorac Dis 2011 0.99
9 New modalities of cancer treatment for NSCLC: focus on immunotherapy. Cancer Manag Res 2014 0.94
10 Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer. Oncologist 2012 0.91
11 Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes. Ther Adv Med Oncol 2011 0.87
12 Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer. Cancer Med 2013 0.86
13 Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? Ther Adv Med Oncol 2013 0.86
14 Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol 2015 0.83
15 Lung cancer vaccines. Cancer J 2011 0.82
16 Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies. Cancer J 2013 0.82
17 Tecemotide: an antigen-specific cancer immunotherapy. Hum Vaccin Immunother 2014 0.81
18 What lies within: novel strategies in immunotherapy for non-small cell lung cancer. Oncologist 2013 0.81
19 Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. Expert Rev Vaccines 2011 0.80
20 Actual status of therapeutic vaccination in non-small cell lung cancer. Contemp Oncol (Pozn) 2014 0.80
21 Cellular and molecular immunology of lung cancer: therapeutic implications. Expert Rev Clin Immunol 2014 0.79
22 Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions. J Int AIDS Soc 2015 0.78
23 Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg 2015 0.77
24 Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. J Natl Compr Canc Netw 2013 0.77
25 New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015 0.76
26 Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol 2014 0.75
27 Challenges and opportunities for cancer vaccines in the current NSCLC clinical scenario. Curr Top Med Chem 2013 0.75
28 Therapeutic cancer vaccines and combination immunotherapies involving vaccination. Immunotargets Ther 2014 0.75
29 Therapeutic vaccines in non-small cell lung cancer. Immunotargets Ther 2013 0.75
Next 100